Literature DB >> 7858251

Transient increase in circulating donor leukocytes after allogeneic transfusions in immunocompetent recipients compatible with donor cell proliferation.

T H Lee1, E Donegan, S Slichter, M P Busch.   

Abstract

Donor leukocytes in therapeutic blood components are implicated in transfusion-related complications ranging from alloimmunization to graft-versus-host disease (GVHD) to viral transmission and reactivation. To further characterize the kinetics of donor leukocyte clearance after allogeneic transfusion, we developed allele-specific polymerase chain reaction (PCR) assays directed at a single-copy Y chromosome gene and HLA class II alleles. These assays enable sensitive detection and quantitation of donor leukocytes at concentrations ranging from one cell to greater than 1,000 cells per 125 microL of recipient blood. When applied to serial samples from five consecutive orthopedic surgery patients who met study criteria, we observed 99.9% clearance of donor leukocytes over the initial 2 days posttransfusion, followed by a transient, 1-log increase in circulating donor leukocytes on days 3 to 5. This phenomenon was reproduced in a canine transfusion model, where the transient donor leukocyte expansion phase was prevented by gamma irradiation of donor blood, and was not observed after transfusions into alloimmunized dogs. We hypothesize that this transient increase in circulating allogeneic donor cells represents one arm of an in vivo mixed lymphocyte reaction, with activated donor T lymphocytes proliferating in an abortive GVHD reaction to HLA-incompatible recipient cells. Further investigation of this phenomenon should provide insight into the mechanisms involved in donor-recipient leukocyte interactions posttransfusion and the relationship of these interactions to leukocyte-induced complications.

Entities:  

Mesh:

Year:  1995        PMID: 7858251

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

1.  Blood group genotyping facilitates transfusion of beta-thalassemia patients.

Authors:  Lilian Castilho; Maria Rios; Jordão Pellegrino; Sara T O Saad; Fernando F Costa
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

2.  Benefits of blood group genotyping in multi-transfused patients from the south of Brazil.

Authors:  Gláucia Andréia Soares Guelsin; Ana Maria Sell; Lilian Castilho; Viviane Lika Masaki; Fabiano Cavalcante Melo; Margareth Naomi Hashimoto; Tatiana Takahashi Higa; Loide Souza Hirle; Jeane Eliete Laguila Visentainer
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

3.  High prevalence of complement component C6 deficiency among African-Americans in the south-eastern USA.

Authors:  Z Zhu; T P Atkinson; K T Hovanky; S B Boppana; Y L Dai; P Densen; R C Go; J S Jablecki; J E Volanakis
Journal:  Clin Exp Immunol       Date:  2000-02       Impact factor: 4.330

4.  Can post-mortem blood be used for DNA profiling after peri-mortem blood transfusion?

Authors:  E A M Graham; M Tsokos; G N Rutty
Journal:  Int J Legal Med       Date:  2005-12-10       Impact factor: 2.686

Review 5.  Transfusion-associated microchimerism: the hybrid within.

Authors:  Evan M Bloch; Rachael P Jackman; Tzong-Hae Lee; Michael P Busch
Journal:  Transfus Med Rev       Date:  2012-10-24

6.  Absence of transfusion-associated microchimerism in pediatric and adult recipients of leukoreduced and gamma-irradiated blood components.

Authors:  Rosa Sanchez; Tzong-Hae Lee; Li Wen; Leilani Montalvo; Cathy Schechterly; Camilla Colvin; Harvey J Alter; Naomi L C Luban; Michael P Busch
Journal:  Transfusion       Date:  2011-10-07       Impact factor: 3.157

7.  Leukodepleted blood components do not remove the potential for long-term transfusion-associated microchimerism in Australian major trauma patients.

Authors:  Rena Hirani; Zsolt J Balogh; Natalie J Lott; Jeremy M Hsu; David O Irving
Journal:  Chimerism       Date:  2015-08-07

8.  Genotyping patients with recent blood transfusions.

Authors:  Michelle Ng Gong; Yang Sai; Wei Zhou; B Taylor Thompson; Li-Lian Xu; David C Christiani
Journal:  Epidemiology       Date:  2003-11       Impact factor: 4.822

9.  Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.

Authors:  Andrea Boni; Pawel Muranski; Lydie Cassard; Claudia Wrzesinski; Chrystal M Paulos; Douglas C Palmer; Luca Gattinoni; Christian S Hinrichs; Chi-Chao Chan; Steven A Rosenberg; Nicholas P Restifo
Journal:  Blood       Date:  2008-09-17       Impact factor: 22.113

10.  Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic mice.

Authors:  Thuy-Vi V Nguyen; Lin Shen; Lilith Vander Griend; Lisa N Quach; Nadia P Belichenko; Nay Saw; Tao Yang; Mehrdad Shamloo; Tony Wyss-Coray; Stephen M Massa; Frank M Longo
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.